Mode
Text Size
Log in / Sign up
Phase 3 Completed N=80 Randomized Double-blind Prevention

Effect of Intake of Glycin Max (L.) Merr. Peel Extract on Body Fat and Body Weight

Source: ClinicalTrials.gov NCT02108691 ↗
Enrolled (actual)
80
Serious AEs
0.0%
Results posted
May 2015
Primary outcomePrimary: Changes in Body Fat Mass — 16790.27; 18223.75; 20174.10; 21474.88 g

Summary

The investigators performed a 8-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Glycin max (L.) Merr. peel extract on decrement of body fat. The investigators measured decrement of body fat parameters , including Body Fat Mass, Percent Body Fat, weight and BMI(body mass index), and monitored their blood pressure.

Outcome Measures

OutcomeResultp-value
PRIMARY
Changes in Body Fat Mass
16790.27; 18223.75; 20174.10; 21474.88
SECONDARY
Changes in Percent Body Fat
24.28; 25.15; 28.52; 28.76
SECONDARY
Changes in Weight
78.50; 81.46; 77.36; 80.60
SECONDARY
Changes in BMI(Body Mass Index)
27.62; 28.29; 27.22; 28.00
SECONDARY
Changes in LDLc
122.50; 113.81; 98.47; 104.06
SECONDARY
Changes in Non-HDLc
171.63; 166.52; 128.78; 137.39
SECONDARY
Changes in LDLc/HDLc
2.21; 2.04; 2.02; 2.15

Eligibility Criteria

Inclusion Criteria

  • Males and females 19-65 years old
  • BMI(body mass index) ≥ 25 kg/m^2 or WC(Waist Circumference) ≥ 90(men), WC ≥ 85(women)
  • Able to give informed consent

Exclusion Criteria

  • Significant variation in weight(more 10%) in the past 3 months
  • Allergic or hypersensitive to any of the ingredients in the test products
  • History of reaction to any of the test products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery
  • History of alcohol or substance abuse
  • Participation in any other clinical trials within past 2 months
  • Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study
  • Pregnant or lactating women etc.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02108691). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search